At a glance
ClinicalIndex Comparison RecordN/ACompleted· 268 enrolled
Drug / intervention
Proxalutamide +1 moredrug
Likely dose
Proxalutamide 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Anti-Androgen Treatment for COVID-19
In Brief
A clinical study evaluating Proxalutamide and Standard of Care for COVID-19 and 5 related conditions. Completed, enrolled 268 participants across 1 site.
Detailed Summary
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate Cancer, Benign Prostatic Hyperplasia, SARS (Severe Acute Respiratory Syndrome)
CountriesBrazil
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartOct 2020
Primary CompletionDec 2020
Study CompletionJan 2021
TodayJul 2026
First PostedJun 24, 2020
Enrollment StartOct 21, 2020
Primary CompletionDec 24, 2020
Study CompletionJan 21, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 6.0 years ago
Interventions
Proxalutamidedrug
200 mg q.d.
Standard of Careother
Standard of care as determined by the PI